DICE Therapeutics (DICE) Stock Forecast, Price & News

11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for DICE Therapeutics in the last twelve months. There are currently 1 hold rating and 10 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" DICE shares.
View DICE analyst ratings or view top-rated stocks.

11 brokerages have issued 12 month price targets for DICE Therapeutics' shares. Their DICE share price forecasts range from $38.00 to $77.00. On average, they predict the company's stock price to reach $62.60 in the next twelve months. This suggests a possible upside of 106.2% from the stock's current price.
View analysts price targets for DICE or view top-rated stocks among Wall Street analysts.

DICE Therapeutics' stock was trading at $31.20 at the beginning of the year. Since then, DICE stock has decreased by 2.7% and is now trading at $30.36.
View the best growth stocks for 2023 here.

DICE Therapeutics saw a decline in short interest in May. As of May 15th, there was short interest totaling 8,010,000 shares, a decline of 9.0% from the April 30th total of 8,800,000 shares. Based on an average trading volume of 526,900 shares, the days-to-cover ratio is presently 15.2 days. Approximately 20.8% of the shares of the stock are sold short.
View DICE Therapeutics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our DICE earnings forecast.

DICE Therapeutics, Inc. (NASDAQ:DICE) released its quarterly earnings results on Wednesday, March, 15th. The company reported ($0.51) EPS for the quarter, missing analysts' consensus estimates of ($0.49) by $0.02.

ETFs with the largest weight of DICE Therapeutics (NASDAQ:DICE) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), First Trust Multi-Manager Small Cap Opportunities ETF (MMSC), Principal Healthcare Innovators ETF (BTEC), iShares U.S. Pharmaceuticals ETF (IHE), iShares Micro-Cap ETF (IWC) and Invesco Nasdaq Biotechnology ETF (IBBQ).

(DICE) raised $160 million in an IPO on Wednesday, September 15th 2021. The company issued 10,000,000 shares at a price of $15.00-$17.00 per share.

DICE Therapeutics trades on the NASDAQ under the ticker symbol "DICE."

DICE Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include FMR LLC (11.90%), Avoro Capital Advisors LLC (8.28%), Price T Rowe Associates Inc. MD (6.82%), BlackRock Inc. (6.31%), Armistice Capital LLC (2.88%) and Baker BROS. Advisors LP (2.17%). Insiders that own company stock include James Paul Scopa, John R Jacobsen, Kevin Judice, Lu Timothy, Ra Capital Management, LP, Richard H Scheller and Scott M Robertson.
View institutional ownership trends.

Shares of DICE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of DICE stock can currently be purchased for approximately $30.36.

DICE Therapeutics (NASDAQ:DICE) has a market capitalization of $1.45 billion and generates $1.13 million in revenue each year. The company earns $-83,890,000.00 in net income (profit) each year or ($2.18) on an earnings per share basis.

DICE Therapeutics' mailing address is 279 E. GRAND AVENUE SUITE 300 LOBBY B, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.dicemolecules.com. The company can be reached via phone at 650-566-1420 or via email at investors@dicetx.com.